Careers  |  Sign In  |  Register

CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC

Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell lung cancer (NSCLC). Dr. Ramalingam asserts that most of these salient toxicities occur within the first six months of treatment and are often manageable.

Learn more by clicking here.